Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹ Recommendation based ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Hi, I am Sebastian Sattui. I'm an assistant ...
All About Polymyalgia Rheumatica and Temporal Arteritis: From Symptoms to Treatments: By Shreoshree Chakrabarty Polymyalgia rheumatica (PMR) and temporal arteritis, also known as giant cell arteritis ...
However, patient-reported scores were not significantly better in the tocilizumab group. Tocilizumab (Actemra) appears to lead to meaningful results in patients with active polymyalgia rheumatica ...
The Global Healthy Living Foundation (GHLF) is excited to present innovative and transformative research at the American College of Rheumatology (ACR) Convergence 2024 in Washington DC. This marks ...
The whole-body MRI revealed similar inflammation levels in both patients with new arthralgia and those with new inflammatory arthritis after exposure to immune checkpoint inhibitors (ICIs), showing ...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results